← All Mesothelioma Navy Flashcard Decks

Mesothelioma Navy Quality & Compliance Flashcards

7 cards from real Mesothelioma Navy practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Mesothelioma Navy Quality & Compliance flashcards as text
  1. Which biopsy method is considered the gold standard for definitively diagnosing malignant pleural mesothelioma in a Navy veteran?

    Answer: Thoracoscopic (VATS) pleural biopsy with immunohistochemical staining

    Video-assisted thoracoscopic surgery (VATS) with pleural biopsy followed by immunohistochemical staining is the gold standard for confirming a mesothelioma diagnosis.

  2. The International Mesothelioma Interest Group (IMIG) staging system for pleural mesothelioma uses Stage I through IV. What does Stage IV designation mean for treatment compliance planning?

    Answer: Distant metastases are present, typically limiting curative surgical options

    IMIG Stage IV indicates distant metastatic spread, which generally excludes patients from curative surgery and shifts compliance planning toward systemic therapy and palliative care.

  3. Under NCCN (National Comprehensive Cancer Network) guidelines, which first-line chemotherapy regimen is recommended for unresectable pleural mesothelioma?

    Answer: Cisplatin plus pemetrexed (Alimta)

    Cisplatin plus pemetrexed is the NCCN-recommended first-line chemotherapy combination for unresectable malignant pleural mesothelioma, with demonstrated survival benefit in clinical trials.

  4. Quality compliance in mesothelioma pathology requires distinguishing mesothelioma from lung adenocarcinoma. Which biomarker panel is most commonly used?

    Answer: Calretinin and WT-1 (positive in mesothelioma) vs. TTF-1 and Napsin A (positive in adenocarcinoma)

    Pathologists use a panel including calretinin and WT-1 (mesothelioma markers) versus TTF-1 and Napsin A (adenocarcinoma markers) to ensure accurate differential diagnosis.

  5. A quality mesothelioma center must offer palliative pleurodesis for symptomatic pleural effusion. What is the PRIMARY goal of this procedure?

    Answer: Prevent fluid from re-accumulating in the pleural space to relieve breathlessness

    Pleurodesis creates adhesions between pleural layers to prevent recurrent fluid accumulation, providing significant relief from the breathlessness caused by malignant pleural effusion.

  6. Under accreditation standards for cancer centers, how frequently must a mesothelioma patient's treatment response be formally reassessed?

    Answer: After every 2–3 treatment cycles using imaging and clinical evaluation

    Accreditation standards require formal reassessment with imaging after every 2–3 chemotherapy or immunotherapy cycles to evaluate treatment response and adjust the care plan.

  7. Which immunotherapy drug combination received FDA approval for first-line treatment of unresectable pleural mesothelioma in 2020, expanding compliance treatment options?

    Answer: Nivolumab plus ipilimumab (CheckMate 743)

    The CheckMate 743 trial demonstrated superior overall survival with nivolumab plus ipilimumab versus chemotherapy, leading to FDA approval as a first-line option for unresectable pleural mesothelioma.